Thymic malignancies represent a wide range of clinical, histological and molecular entities, with probably considerable heterogeneity even among tumors of the same histotype. Systemic chemotherapy with cisplatin-based regimens continues to represent the standard of care in metastatic or inoperable refractory/recurrent diseases and ADOC regimen (including cisplatin, doxorubicin, vincristine and cyclophosphamide) demonstrated the longer overall response rate and median survival in the first line setting, although no randomized trial is available; and there is still a lack of standard treatment after first-line failure. To date research efforts are focused on translational studies on molecular pathways involved in thymic tumors carcinogenesis, aimed to better understand and predict the efficacy of chemotherapy and targeted therapy. Recent molecular characterization includes identification of a number of oncogenes, tumor suppressor genes, chromosomal aberrations, angiogenic factors, and tumor invasion factors involved in cellular survival and proliferation and in tumor growth. The use of biologic drugs is currently not recommended in a routine practice because there are limited data on their therapeutic role in thymic epitelial tumors. Because of the lack of data from adequate-sized, prospective trials are required for validation and the enrolment of patients with advanced disease into available clinical trials has to be encouraged.
|Data di pubblicazione:||2014|
|Titolo:||Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review.|
|Autore/i:||Berardi, R; De Lisa, M; Pagliaretta, S; Onofri, A; Morgese, F; Savini, A; Ballatore, Z; Caramanti, M; Santoni, M; Mazzanti, P; Cascinu, Stefano|
|Codice identificativo ISI:||WOS:000333854700002|
|Codice identificativo Scopus:||2-s2.0-84896739452|
|Citazione:||Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. / Berardi, R; De Lisa, M; Pagliaretta, S; Onofri, A; Morgese, F; Savini, A; Ballatore, Z; Caramanti, M; Santoni, M; Mazzanti, P; Cascinu, Stefano. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 40:4(2014), pp. 495-506.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris